Study of Iptacopan for adults with PNH in China
Treatments studied
Part of Blood & lymphatic clinical trials.
This study looks at how well iptacopan works for people with PNH (a condition where red blood cells break down too quickly). It is for adults who have never used certain treatments or who have been on other similar medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with PNH (a type of blood disorder)
- You have not had any previous treatments like eculizumab or ravulizumab (for one group), or you have been on them for at least 3 months (for another group)
- You are starting iptacopan therapy within 60 days of agreeing to join
- You have had vaccinations against meningitis and pneumonia at least 2 weeks before starting iptacopan (or you will take antibiotics if needed)
- You are not pregnant, breastfeeding, or planning to get pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people who have already completed the Phase 2 study of LP-005 and may continue receiving it. It checks how safe and effective the drug is over a longer period.
This trial tests a medicine called iptacopan for people with paroxysmal nocturnal hemoglobinuria (a rare blood disorder) or C3 glomerulopathy (a kidney disease). It aims to see if the drug is safe and effective for Korean patients.
This study looks at how the medicine pegcetacoplan works in real life for adults with paroxysmal nocturnal hemoglobinuria (PNH). It may help doctors understand expected benefits and everyday use patterns.
This study tests a new oral medication called NTQ5082 for people with PNH who have not been treated with a complement inhibitor before. It aims to see if the drug can reduce the breakdown of red blood cells and improve anemia.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This Phase 2 study tests how well and how safely NM8074 works for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not recently received a similar “complement inhibitor” medicine. It may help reduce PNH-related blood cell breakdown and anemia, and it will closely monitor side effects.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.